{"organizations": [], "uuid": "3876d50eef64600c5ad233d7092ff48774cd1a50", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-alnylam-receives-positive-opinion/brief-alnylam-receives-positive-opinion-for-orphan-drug-designation-in-eu-for-aln-ttrsc02-for-treatment-of-transthyretin-mediated-amyloidosis-idUSASO0003OG", "country": "US", "domain_rank": 408, "title": "BRIEF-Alnylam Receives Positive Opinion For Orphan Drug Designation In EU For ALN-TTRsc02, For Treatment Of Transthyretin-Mediated Amyloidosis", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-23T14:25:00.000+03:00", "replies_count": 0, "uuid": "3876d50eef64600c5ad233d7092ff48774cd1a50"}, "author": "", "url": "https://www.reuters.com/article/brief-alnylam-receives-positive-opinion/brief-alnylam-receives-positive-opinion-for-orphan-drug-designation-in-eu-for-aln-ttrsc02-for-treatment-of-transthyretin-mediated-amyloidosis-idUSASO0003OG", "ord_in_thread": 0, "title": "BRIEF-Alnylam Receives Positive Opinion For Orphan Drug Designation In EU For ALN-TTRsc02, For Treatment Of Transthyretin-Mediated Amyloidosis", "locations": [], "entities": {"persons": [], "locations": [{"name": "eu", "sentiment": "none"}, {"name": "european union", "sentiment": "none"}], "organizations": [{"name": "treatment of transthyretin-mediated amyloidosis", "sentiment": "negative"}, {"name": "eu", "sentiment": "none"}, {"name": "alnylam pharmaceuticals inc", "sentiment": "none"}, {"name": "alnylam", "sentiment": "none"}, {"name": "treatment of transthyretin-mediated amyloidosis reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 25 AM / Updated 8 minutes ago BRIEF-Alnylam Receives Positive Opinion For Orphan Drug Designation In EU For ALN-TTRsc02, For Treatment Of Transthyretin-Mediated Amyloidosis Reuters Staff 1 Min Read \nApril 23 (Reuters) - Alnylam Pharmaceuticals Inc: \n* ALNYLAM RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ALN-TTRSC02, A SUBCUTANEOUSLY DELIVERED INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF TRANSTHYRETIN-MEDIATED AMYLOIDOSIS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-23T14:25:00.000+03:00", "crawled": "2018-04-23T14:36:17.028+03:00", "highlightTitle": ""}